What it is and how it works
From the published literature on PNC-27; the papers are listed at the end. Research summary, not a recommendation.
What it is
PNC-27 is a synthetic research peptide built from two parts: residues 12 to 26 of the human tumour-suppressor protein p53 (the stretch that binds the protein HDM-2) joined to penetratin, a short membrane-crossing sequence. PNC-28 is a shorter version using residues 17 to 26. Almost all published work comes from one research group at SUNY Downstate in New York, and all of it is in cultured cells, patient tumour cells grown in the lab, and mice.
How it works
HDM-2 (also called MDM2) is a protein that normally sits inside cells and tags p53 for destruction. The research group reported that many cancer cells, but few normal cells, carry HDM-2 on their outer membrane. In their lab work PNC-27 bound to this membrane HDM-2, the bound pairs joined up to form pores through the membrane, and the cell contents leaked out, killing the cell by necrosis (bursting) rather than by programmed cell death. Normal cells with little membrane HDM-2 were reported to be unaffected. These mechanism claims have not been independently confirmed by other laboratories.
What it has been studied for
- Killing of cancer cell lines with membrane HDM-2 (lab studies)
- Leukaemia cells versus normal blood-forming cells (lab studies)
- Patient-derived ovarian cancer cells (lab studies)
- Pancreatic tumour growth in mice (PNC-28, animal study)
- Pore formation in cancer-cell membranes (lab studies and reviews)
Strength of the evidence
Animal and lab studiesThe published evidence is cell-culture work and mouse tumour studies, nearly all from a single group; no human study has been published.
What the literature reports on safety
The group reported no harm to normal cells in culture and no obvious off-target effects in mice, but no human safety data exist. PNC-27 is not approved by the FDA or any regulator and has not entered a registered clinical trial. One author of the main review declared employment by a company developing the peptide, and the findings have not been reproduced by an independent group.
Key papers
Review · Pincus MR, Silberstein M, et al. · Biomedicines (2024) · PMID 38927351
The developing group reviewed its work and described PNC-27 and PNC-28 binding membrane HDM-2 and forming pores that burst cancer cells, with tumour control in mice and no effect on normal cells.
Anti-cancer peptides from ras-p21 and p53 proteins (opens in a new tab)
Review · Pincus MR, Fenelus M, et al. · Current Pharmaceutical Design (2011) · PMID 21728981
An earlier review from the same group of the anticancer peptides it designed from the p53 and ras-p21 proteins, including PNC-27 and PNC-28.
Lab (in vitro) · Sarafraz-Yazdi E, Bowne WB, et al. · Proceedings of the National Academy of Sciences of the USA (2010) · PMID 20080680
Found HDM-2 in the membranes of several cancer cell lines but not normal lines, and normal cells became susceptible to PNC-27 once engineered to carry membrane HDM-2.
Lab (in vitro) · Sarafraz-Yazdi E, Mumin S, et al. · Biomedicines (2022) · PMID 35625682
Reported that PNC-27 bound membrane HDM-2 and formed pores selectively in cancer-cell membranes, leading to cell lysis.
Lab (in vitro) · Thadi A, Lewis L, et al. · Anticancer Research (2020) · PMID 32878773
In culture, PNC-27 caused necrosis of leukaemia cells but not of normal blood-forming cells.
Sources checked: PubMed/PMC (E-utilities esummary and abstracts on every PMID), ClinicalTrials.gov (no registered trial found), written 2026-11-06.
No sources yet
None of the three teachers' sources we have indexed discuss PNC-27 yet. This page will fill in as sources are added.
Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.
Disclaimer: for research purposes only
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.